Category Archives: Business and Investments

Latest From Business and Investments

Indices, IPOs, and New Drug Approvals – Update April 3rd 2012

Index-March-20121

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Dealing with Rejection, the Regulatory Kind

trytry-again

The ubiquitous CRL in biotech has made its way into the news headlines again. But is the Complete Response Letter a game-changing hurdle for a biotech, or is it par for the course these days? It turns out that almost half of NDA/BLA filings get rejected by the FDA on the 1st round. However, most companies resubmit their application, and by the 2nd review 75% of drugs gain FDA approval. After heading for a 3rd Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Meet 2011′s Buzz of BIO Winner, Amrita Therapeutics

BuzzofBIOLogo

2011 Buzz of BIO Health Winner Amrita Therapeutics is a bio-pharma discovery company based in Ahmedabad, Gujarat, pursuing the development of novel, multiple disease targeting therapies for cancer. Last year, they won the Buzz of BIO Contest for the 2011 BIO International Convention, where industry executives and leaders voted on their favorite biotech companies. BIO recently spoke with Susan Finston, the CEO of Amrita Therapeutics, to get their thoughts on the contest, last year’s BIO Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

BIO Europe Spring 2012 – Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public market performance in the US vs other sectors Private funding environment. Drug pipeline deal volume. For a copy of the slides, they can be found here.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

Exhibitor Partnering: A Toolkit

attendessBusinessForum

Traditionally, all private meetings at the BIO International convention have taken place in the BIO Business Forum®. If you were partnering, you would be found in a booth space within the Business Forum, end of story. This year, however, there’s Exhibitor Partnering, a completely new feature of the BIO International Convention and the BIO Business Forum. The Business Forum will still very much exist, and you can see exactly where in the map below of Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,